One-week therapy with oral albendazole in hookworm-related cutaneous larva migrans

A retrospective study on 78 patients

Stefano Veraldi, Silvia Bottini, Gaetano Rizzitelli, Maria Chiara Persico

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

We evaluated retrospectively the efficacy and tolerability of oral albendazole (400 mg/day for 1 week) in 78 patients with hookworm-related cutaneous larva migrans characterized by multiple and/or extensive lesions. The diagnosis was based on history and the clinical picture. Neither topical or systemic drugs nor physical treatments were used. All patients were followed-up for at least 3 months after the therapy. All patients were cured at the end of the therapy. The disappearance of pruritus was reported after 23 days and skin lesions after 57 days of therapy. One patient reported nausea and abdominal pain; another patient reported worsening of pruritus: in both cases it was not necessary to stop the therapy. No recurrences were observed during follow-up. One week of therapy with 400 mg/day oral albendazole is very effective (cure rate: 100%) in patients with cutaneous larva migrans characterized by multiple and/or extensive lesions. This therapeutical regimen is not accompanied by the appearance of new and/or more severe side effects.

Original languageEnglish
Pages (from-to)189-191
Number of pages3
JournalJournal of Dermatological Treatment
Volume23
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

Larva Migrans
Ancylostomatoidea
Albendazole
Retrospective Studies
Pruritus
Therapeutics
Nausea
Abdominal Pain
History
Recurrence
Skin
Pharmaceutical Preparations

Keywords

  • Albendazole
  • Hookworm-related cutaneous larva migrans

ASJC Scopus subject areas

  • Dermatology

Cite this

One-week therapy with oral albendazole in hookworm-related cutaneous larva migrans : A retrospective study on 78 patients. / Veraldi, Stefano; Bottini, Silvia; Rizzitelli, Gaetano; Persico, Maria Chiara.

In: Journal of Dermatological Treatment, Vol. 23, No. 3, 06.2012, p. 189-191.

Research output: Contribution to journalArticle

@article{a5e2bccfe81343ce918b409de161bef7,
title = "One-week therapy with oral albendazole in hookworm-related cutaneous larva migrans: A retrospective study on 78 patients",
abstract = "We evaluated retrospectively the efficacy and tolerability of oral albendazole (400 mg/day for 1 week) in 78 patients with hookworm-related cutaneous larva migrans characterized by multiple and/or extensive lesions. The diagnosis was based on history and the clinical picture. Neither topical or systemic drugs nor physical treatments were used. All patients were followed-up for at least 3 months after the therapy. All patients were cured at the end of the therapy. The disappearance of pruritus was reported after 23 days and skin lesions after 57 days of therapy. One patient reported nausea and abdominal pain; another patient reported worsening of pruritus: in both cases it was not necessary to stop the therapy. No recurrences were observed during follow-up. One week of therapy with 400 mg/day oral albendazole is very effective (cure rate: 100{\%}) in patients with cutaneous larva migrans characterized by multiple and/or extensive lesions. This therapeutical regimen is not accompanied by the appearance of new and/or more severe side effects.",
keywords = "Albendazole, Hookworm-related cutaneous larva migrans",
author = "Stefano Veraldi and Silvia Bottini and Gaetano Rizzitelli and Persico, {Maria Chiara}",
year = "2012",
month = "6",
doi = "10.3109/09546634.2010.544707",
language = "English",
volume = "23",
pages = "189--191",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - One-week therapy with oral albendazole in hookworm-related cutaneous larva migrans

T2 - A retrospective study on 78 patients

AU - Veraldi, Stefano

AU - Bottini, Silvia

AU - Rizzitelli, Gaetano

AU - Persico, Maria Chiara

PY - 2012/6

Y1 - 2012/6

N2 - We evaluated retrospectively the efficacy and tolerability of oral albendazole (400 mg/day for 1 week) in 78 patients with hookworm-related cutaneous larva migrans characterized by multiple and/or extensive lesions. The diagnosis was based on history and the clinical picture. Neither topical or systemic drugs nor physical treatments were used. All patients were followed-up for at least 3 months after the therapy. All patients were cured at the end of the therapy. The disappearance of pruritus was reported after 23 days and skin lesions after 57 days of therapy. One patient reported nausea and abdominal pain; another patient reported worsening of pruritus: in both cases it was not necessary to stop the therapy. No recurrences were observed during follow-up. One week of therapy with 400 mg/day oral albendazole is very effective (cure rate: 100%) in patients with cutaneous larva migrans characterized by multiple and/or extensive lesions. This therapeutical regimen is not accompanied by the appearance of new and/or more severe side effects.

AB - We evaluated retrospectively the efficacy and tolerability of oral albendazole (400 mg/day for 1 week) in 78 patients with hookworm-related cutaneous larva migrans characterized by multiple and/or extensive lesions. The diagnosis was based on history and the clinical picture. Neither topical or systemic drugs nor physical treatments were used. All patients were followed-up for at least 3 months after the therapy. All patients were cured at the end of the therapy. The disappearance of pruritus was reported after 23 days and skin lesions after 57 days of therapy. One patient reported nausea and abdominal pain; another patient reported worsening of pruritus: in both cases it was not necessary to stop the therapy. No recurrences were observed during follow-up. One week of therapy with 400 mg/day oral albendazole is very effective (cure rate: 100%) in patients with cutaneous larva migrans characterized by multiple and/or extensive lesions. This therapeutical regimen is not accompanied by the appearance of new and/or more severe side effects.

KW - Albendazole

KW - Hookworm-related cutaneous larva migrans

UR - http://www.scopus.com/inward/record.url?scp=84861054571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861054571&partnerID=8YFLogxK

U2 - 10.3109/09546634.2010.544707

DO - 10.3109/09546634.2010.544707

M3 - Article

VL - 23

SP - 189

EP - 191

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 3

ER -